Integrated Immune Engineering for Poor Prognosis Cancers

综合免疫工程治疗预后不良的癌症

• 批准号: 10270392
• 负责人: DAVID ANDREW LARGAESPADA
• 金额: $ 192.1万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-16 至 2026-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10270392
• 关键词: Accounting; Antitumor Response; Apoptosis; Area; Benefits and Risks; Biomedical Engineering; Biophysics; Blood; CAR T cell therapy; Cancer Control; Cancer Patient; Cancer Prognosis; Cells; Chemicals; Clinical; Clinical Trials; Collaborations; Complex; Computers; Development; Diagnosis; Diffuse; Economics; Effectiveness; Engineering; Environment; Explosion; Failure; Genetic; Genetic Engineering; Genetically Engineered Mouse; Genome engineering; Glioblastoma; Growth; Health Benefit; Image; Immune; Immune response; Immune system; Immunocompetent; Immunologics; Immunologist; Immunooncology; Immunotherapeutic agent; Immunotherapy; In Vitro; Infiltration; Liquid substance; Malignant Neoplasms; Malignant neoplasm of brain; Malignant neoplasm of pancreas; Measures; Mechanics; Microfabrication; Modeling; Oncology; Pancreatic Ductal Adenocarcinoma; Patients; Pharmacology; Phase; Physics; Plants; Process; Prognosis; Risk; Signal Transduction; Solid Neoplasm; Stream; System; T-Lymphocyte; Technology; Testing; Therapy trial; Time; Tissues; Translations; Tumor-infiltrating immune cells; anti-tumor immune response; base; biophysical model; cancer cell; cancer therapy; cell motility; clinical risk; computational platform; cost; cytotoxic; engineered T cells; exhaustion; high resolution imaging; high risk; immunoengineering; immunotherapy clinical trials; improved; in vivo; live cell microscopy; model development; models and simulation; nanoscale; optical imaging; optimism; patient population; physical science; pre-clinical assessment; pre-clinical research; preclinical development; programs; response; success; tumor; tumor immunology; tumor progression

ABSTRACT A key limitation to effective immunotherapy is the physical access of immune cells to the cancer cells. We propose to develop a multiscale tumor simulator to predict tumor dynamics based on immune and cancer cell migration and net proliferation as measured quantitatively from live cell microscopy. The tumor simulator will be developed by biomedical engineers working in close collaboration with immunologists and genetic engineers who are developing immunotherapies for pancreatic ductal adenocarcinoma and glioblastoma. The tumor simulator will be a computational platform that will help guide immunotherapy development and so will evolve to become an immunotherapy simulator. In addition, we will integrate state- of-the-art genome engineering and microenvironmental engineering to bring a full suite of engineering approaches to bear on the simulator development. Together, the simulator will be used to make quantitative, testable predictions that are then tested experimentally using pharmacological and genetic perturbations. By iterative model development we will test our central hypothesis that immune cell proximity is a major determinant of effective anti-tumoral immune response, and limiting to effective immunotherapy of solid tumors. Altogether, our Program Project will develop a comprehensive biophysics-based simulator to predict tumor progression and accelerate immunotherapy development.

摘要 有效免疫疗法的一个关键限制是免疫细胞对癌细胞的物理访问。我们 我建议开发一个多尺度肿瘤模拟器，以预测基于免疫和癌症的肿瘤动力学 如活细胞显微镜定量测量的细胞迁移和净增殖。肿瘤 模拟器将由生物医学工程师与免疫学家密切合作开发， 正在开发胰腺导管腺癌免疫疗法的基因工程师， 胶质母细胞瘤肿瘤模拟器将是一个计算平台，将有助于指导免疫治疗 开发，因此将演变为免疫治疗模拟器。此外，我们将整合国家- 最先进的基因组工程和微环境工程， 模拟器开发的方法。总之，模拟器将用于使 定量的，可测试的预测，然后使用药理学和遗传学实验测试 扰动通过迭代模型开发，我们将测试我们的中心假设，即免疫细胞接近 是有效抗肿瘤免疫应答的主要决定因素，并限制有效的免疫治疗 实体肿瘤的总而言之，我们的计划项目将开发一个全面的基于生物制药学的模拟器 预测肿瘤进展并加速免疫疗法的发展。